Objective: CMV is an important pathogen in immunocompromised hosts, including patients with AIDS, neonates and transplant recipients. This infection develops in 70-90 % of transplant patients. Upper GI symptoms in solid organ recipient are common (20 %) and clinical signs are more serious in 10 % of cases.